A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

BACKGROUND: The peak of the global COVID-19 pandemic has not yet been reached, and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of viral replication, some patients develop a second illness phase in which the h...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanassche, T., Engelen, M. M., Van Thillo, Q., Wauters, J., Gunst, J., Wouters, C., Vandenbriele, C., Rex, S., Liesenborghs, L., Wilmer, A., Meersseman, P., Van den Berghe, G., Dauwe, D., Verbeke, G., Thomeer, M., Fivez, T., Mesotten, D., Ruttens, D., Heytens, L., Dapper, I., Tuyls, S., De Tavernier, B., Verhamme, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724460/
https://www.ncbi.nlm.nih.gov/pubmed/33298149
http://dx.doi.org/10.1186/s13063-020-04878-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724460/
https://www.ncbi.nlm.nih.gov/pubmed/33298149
http://dx.doi.org/10.1186/s13063-020-04878-y

Ejemplares similares